Feline Infectious Peritonitis (FIP) is a fatal disease caused by mutations in feline coronaviruses (FCoV), and was once regarded as a "feline terminal disease". Traditional therapies can only alleviate the symptoms, with a cure rate of less than 5%. 2018, Professor Pedersen's team at the University of California, Davis, USA, demonstrated Nukleosid analogini birinchi martaGs -441524Virusli RNN polimerazasini yo'qotganligi sababli, FICAL RNN polimerazasini 2025 yilga kelib, 500 dan oshiq bo'lgan, -441524 ni mag'lubiyatga uchratib, veterinariyadagi eng ko'p ishlatiladigan antiviral agentlardan biri bo'lgan. Tibbiyot .
Virusli replikatsiya zanjirining aniq bloklanishi
GS-441524 is the primary active metabolite of raltegravir (Remdesivir), whose molecular structure contains a cytidine nucleoside backbone and a 1'-cyano modifying moiety. In cats, the drug is phosphorylated by cellular kinases to the nucleoside triphosphate (NTP) form, and the product can compete with natural ATP for binding to the catalytic site of viral RNA-dependent RNA polymerase (RdRp), thereby terminating the extension of the viral RNA strand. Experimental data showed that the half inhibitory concentration (EC50) of GS-441524 against FIP virus (FIPV) was only 0.78 μM, which was much lower than the cytotoxicity concentration (CC50>100 mkm), juda yuqori terapevtik indeks .
GC376 dan farqli o'laroq (3C NazrīC Axibitor), GS -441524 virusli replikotni SME sintezida (-441524 virusli replikatsiya bosqichida . Ushbu maqsadli mexanizmga jiddiy ta'sir ko'rsatadi GS-441524 to excel in the treatment of both dry FIP (non-exudative) and wet FIP (exudative), with particular breakthrough efficacy in complex cases with neurological or ocular lesions. A 2024 follow-up study at the University of Edinburgh, UK, showed that 83.7% of 307 cats with FIP following the standard protocol to'liq remissiyaga erishildi, shundan 62 foizi pyurbred va 52% 12 oydan kam edi.
Klinik dasturlar
► Davolanish rejimi standartlashtirilgan
2019 yilda GS {{}} klinik tomoni GS {{}} klinik ko'rsatma, Pederen jamoasi tomonidan ishlab chiqilgan, boshlang'ich dozalash uchun asos yaratdi:
Dose gradient: Quruq fIP uchun 4 mg / kg / d gacha bo'lgan dastlabki doz, Neyrologik ishtiroki bilan 8-10 {}} {}} £ 4 mg / d / d uchun
Restimen dizayni: 12 12 Bir necha hafta davomida har 4 hafta serologik monitoring bilan doimiy doimiy ravishda in'ektsiya uchun doimiy ravishda teri orqali inektsiyalash
Kutishni to'xtatish mezonlari: klinik alomatlarning yo'qolishi va zardob nisbati (ALUMIN nisbati (ALUMIN nisbati (A: g) 2 hafta davomida (A: g)
Klinik amaliyot shuni ko'rsatadiki, ushbu rejim avstraliyadagi tanqidiy holatlar 61% dan 79% gacha bo'lgan Melburn-IV} {{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{}}}}}} ning ketma-ket terapiyasini qabul qildi.
► Dozani innovatsiya va etkazib berish optimallashtirish
Teri osti yaralaridagi terilar muammosini hal qilish uchun dunyodagi birinchi gs {{0} -441524 -441524 -441524 Biologik jihatdan xushbo'ylik va qon kontsentratsiyasi 10 mg / kg . dozasi bilan bezatilgan, klinik Taqqoslashlar shuni ko'rsatadiki, og'zaki ma'muriyat in'ektsiya joyining asoratlari 37 foizga qisqaradi, uni ayniqsa ko'p mushuk uy xo'jaliklari va mushukcha davolash uchun mos keladi .
Qattiq holatlar uchun kombinatsiyalangan restüsiya -441524 10} MG -441524 10} MG -441524 10} MG -441524 10 @}} . bo'yicha 45% miqdorida konvulsictionning kombinatsiyasini ko'rsatadi
Samaradorlikni tekshirish
|
|
Klinik ma'lumotlar Davolanish darajasi: Sun'iy emlash virus modelida, ikki kun ketma-ket preparatni qabul qilishning 14 kunligi 100% ga etdi; Tabiiy yuqumli holatlarda 12- haftalik davolash kursi 92% ni tashkil etdi RESPEAPER Boshqarmasi: Qayta davolash tugagandan keyin 6 oy davomida atigi 5,3% ni tashkil etdi va ular ikkinchi davolanishdan keyin 89% regyassiya miqdorini olishlari mumkin Xavfsizlik: 10mg / kg dan kam yoki teng bo'lgan dozada inyeksiya joyida (17%) va vaqtinchalik balandlikdagi og'riqlar (12%), miyelozlik yoki organlarning toksikligi yo'q edi |
|
Xoch turdagi qo'llanilishini qidirish Gs -441524 ning antiviral spektri FIP . . . . . {{Mers-Cove virusi (Mers-Cov) 3- katakchasini tasdiqladi Rolegrosir .2024 dan yuqori Seul Milliy universiteti, Janubiy Koreyaning GS {9} "direktori GS {{9}" GS -441524 GS {{9} "GS -441524 GS -441524 GS-441524 GS -441524 GS-441524 GS-441524 Gsster moduliga egalik qiladi. Isitma virusi 12 zoniotik viruslarni o'z ichiga olgan prinik tadqiqotlar olib borilmoqda. |
|
Bozor manzarasi va me'yoriy muammolar
► Progressiv zanjirni eslash
Hozirgi kunda GS -441524 APIS asosan Xitoyda ishlab chiqariladi va hindcha predexnologiya Com {{{{}}} {{}}} {{{}}} {{}}} va boshqa kompaniyalar tomonidan bir partiyaga yuklab olinadigan mahsulotni tayyorlash uchun butun sanoat zanjiri yaratildi 50 kg bo'lgan 50 kg {{9} Cats {{9} Cats {{9} Cats {{} mushuklarning 2025 yildagi nizomi "EMA" ning 2025 yildagi Nonuni texnologik yangilash . ni tezlashtirishni talab qiladi.
► Himoya siyosati
Yuridik bozorlar: Buyuk Britaniya, Avstraliya, Yaponiya va boshqa davlatlar "Veterinariya dorilari uchun maxsus tasdiqlash kanali" orqali sotish va mahsulotni veterinariya retsepti bilan sotib olish kerak.
Gray Zone: The U.S. FDA still classifies GS-441524 as an "investigational drug", but in 2024, it will be classified as "new drug" by the U.S. FDA. The US FDA still classifies GS -441524 "Yangi tergovli dori", ammo 12 ta shtatlar veterinarlar buni buyurishga ruxsat berishadi, 2024.}} {}}}
Qalbaki inqiroz: FIP Warriors sinovdan o'tkazildi va 7-kunlik kunlik dori-darmonlar va dozaning 17 foizini davolashda davolanishning 17 foizini davolash ishini olib chiqdi .
Kelajakdagi prognoz
Aratus Bio (USA) LEA -441524 . Oldingi dozalash maqsadida "Nanotus Bio (AQSh)" Nanotus Bio (AQSh) "Nanotus Bio (AQSh)" Nanotus Bio (AQSh) "NanokomSTALL ekspertizasi" Nanothristalning oldingi ishg'ol qilinishi "Bitta ma'muriyatdan keyin 28 kundan ko'proq vaqt davomida ushlab turilishi mumkinligini ko'rsatdi .
Kombinatsiyani davolash: Felein interferon ō bilan birgalikda GC376 bilan birgalikda klinik sinovlar, ayniqsa, SHONE3 &}} bilan birgalikda, bu davolanish jarayonini 30% ga qisqartirish mumkin, bu esa 30% .
"Rivojlanish uchun ustuvor antiviral" ga "Rivojlanish uchun ustuvor antiviral" kabi klinik tadqiqotlar va "Lassa" isitmalari viruslari va "Lassa" isitma bo'yicha tadqiqotlar ro'yxati keltirib chiqarmoqda.
O -441524 kashfiyot 2008 yilda millionlab mushaklar uchun mo'ljallangan tibbiyotga ega bo'lgan, bu 2018 yilgi dunyodagi millionlab mushaklar uchun yangi paradigm, bu kichik molekulalarning oxirini yangilash kuchi bilan yangilangan Uzoq davom etadigan formulalar va kombinatsiyalangan davolash usullari, GS -441524 3-asrda . ning eng muhim keng spektrli giyohvand moddalar bo'lgan golosir-sprumdan biri sifatida merosni davom ettirishi kutilmoqda